INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

People assigned to a diet, food or program and measured.

97 studies · page 3 of 5

2011 / Ex vivo study using serum from a randomized/controlled test-meal feeding trial

Serum taken 4 hours after consuming an almond meal reduced osteoclast formation, activity, and gene expression in vitro.

Human osteoclast precursors were cultured with 10% serum obtained from 14 healthy subjects at baseline and 4 hours after consuming 3 macronutrient-balanced test meals containing almonds (60 g), potatoes, or rice. Compared to baseline serum, serum obtained 4 hours after the almond meal reduced osteoclast formation by approximately 20%, TRAP activity by approximately 15%, calcium release by approximately 65%, and the expression of cathepsin K, receptor activator of nuclear factor kB, and matrix metalloproteinase-9 by 13% to 23%. No effects were observed with serum from the potato or rice meals.

Platt ID, Josse AR, Kendall CW, et al. Metabolism, 2011. PMID 20947104

2011 / Randomized crossover trial

High-protein diet raised calcium absorption and excretion without altering bone markers in women

In a randomized crossover trial of 16 postmenopausal women, a high-protein, high-acid-load diet (118 g/d protein) was compared to a low-protein, low-acid-load diet (61 g/d protein) for seven weeks each. The high-protein diet increased fractional calcium absorption (26.5% versus 22.3%, P < 0.05) and urinary calcium excretion (203 versus 156 mg/d, P = 0.005). Net calcium balance did not differ significantly between diets, and bone turnover biomarkers remained unchanged.

NANO counterpoint →

Cao JJ, Johnson LK, Hunt JR J Nutr, 2011. PMID 21248199

2011 / Before-after trial (one-month depletion)

A one-month lycopene-restricted diet significantly decreased antioxidant enzymes and increased the bone resorption marker NTx in postmenopausal women.

Twenty-three healthy postmenopausal women underwent a one-month dietary lycopene-depletion period to assess effects on oxidative stress and bone turnover markers. Dietary restriction led to significant reductions in serum lycopene (p < 0.0001), lutein/zeaxanthin (p < 0.01), and α-/β-carotene (p < 0.05). Catalase and superoxide dismutase were significantly depressed (p < 0.05 and p < 0.005, respectively), glutathione peroxidase increased (p < 0.01), lipid and protein oxidation increases were not significant, and the bone resorption marker NTx significantly increased (p < 0.05).

Mackinnon ES, Rao AV, Rao LG J Nutr Health Aging, 2011. PMID 21365167

2011 / Randomized, double-blind, placebo-controlled pilot trial

Chondroitin sulphate significantly reduced cartilage volume loss starting at 6 months and bone marrow lesions at 12 months in knee osteoarthritis patients.

In a pilot multicentre trial, 69 patients with primary knee osteoarthritis and clinical signs of synovitis were randomised to 800 mg chondroitin sulphate (CS) or placebo once daily for 6 months, followed by a 6-month open-label phase where all patients received CS 800 mg daily. The CS group demonstrated significantly less cartilage volume loss than placebo at 6 months for the global knee (p=0.030), lateral compartment (p=0.015), and tibial plateaus (p=0.002), with significance maintained at 12 months. Significantly lower bone marrow lesion scores occurred in the CS group at 12 months in the lateral compartment (p=0.035) and lateral femoral condyle (p=0.044), while disease symptoms were similar between groups.

Wildi LM, Raynauld JP, Martel-Pelletier J, et al. Ann Rheum Dis, 2011. PMID 21367761

2011 / Open-label clinical pilot study

Açai-fortified fruit juice consumption was followed by reduced pain, improved range of motion, and increased serum antioxidant status in a pilot study.

In an open-label pilot study, 14 participants with pain-associated range of motion limitations consumed 120 mL of an açai-fortified fruit and berry juice blend daily for 12 weeks. Juice consumption resulted in significant pain reduction, improved range of motion measures, and improvement in activities of daily living. Serum antioxidant status improved within 2 weeks and continued through 12 weeks (P < .01), while reductions in C-reactive protein did not reach statistical significance and lipid peroxidation decreased mildly.

Jensen GS, Ager DM, Redman KA, et al. J Med Food, 2011. PMID 21470042

2011 / Randomized controlled trial

Dried plum intake significantly increased ulna and spine bone mineral density compared with dried apple in postmenopausal women.

In a randomized trial, 160 osteopenic postmenopausal women were assigned to receive either 100 g/day of dried plum or dried apple as a comparative control for 12 months, with all participants receiving daily calcium (500 mg) and vitamin D (400 IU). Dried plum significantly increased the BMD of the ulna and spine compared with dried apple. Additionally, only the dried plum group showed significant decreases from baseline in serum bone turnover markers, including bone-specific alkaline phosphatase and tartrate-resistant acid phosphatase-5b.

Hooshmand S, Chai SC, Saadat RL, et al. Br J Nutr, 2011. PMID 21736808

2010 / Randomized controlled trial

Brief, daily high-impact hopping exercise significantly increased femoral neck bone mineral density in premenopausal women.

Premenopausal women were randomly assigned to perform 50 multidirectional hops on one leg 0, 2, 4, or 7 days per week for 6 months. Adjusted femoral neck BMD changes differed between groups (p=0.015), showing changes of -0.3% (-1.2 to 0.6), 0.0% (-1.0 to 1.0), 0.9% (-0.1 to 2.0), and 1.8% (0.8 to 2.8) for 0, 2, 4, and 7 days per week, respectively. While an overall exercise effect was noted across hip sites (p=0.048), changes did not differ significantly between the upper neck, lower neck, and trochanter (p=0.439).

Bailey CA, Brooke-Wavell K Bone, 2010. PMID 20004758

2010 / Randomised single-blind acute cross-over trial

Calcium absorption from soymilk fortified with a proprietary calcium phosphate was comparable to that from cow's milk in osteopenic post-menopausal women.

A randomized single-blind acute crossover study evaluated calcium absorption from soymilk fortified with a proprietary phosphate of calcium compared with cow's milk in 12 osteopenic post-menopausal women. Participants consumed 20 mL of test milk labeled with 185 kBq of 45Ca in 44 mg of calcium carrier to determine the hourly fractional calcium absorption rate (alpha). The mean hourly fractional calcium absorption from fortified soymilk was comparable to that of cow's milk (alpha = 0.65 +/- 0.19 vs. alpha = 0.66 +/- 0.22, p > 0.05).

Tang AL, Walker KZ, Wilcox G, et al. Asia Pac J Clin Nutr, 2010. PMID 20460239

2010 / Randomized controlled trial

Annual high-dose oral vitamin D increased falls and fractures in older women.

A randomized trial assigned 2,256 community-dwelling women aged 70 years or older at high fracture risk to an annual dose of 500,000 IU cholecalciferol or placebo for 3 to 5 years. The vitamin D group experienced more fractures (171 vs 135; incidence RR 1.26, 95% CI 1.00-1.59, P = 0.047) and more falls (incidence RR 1.15, 95% CI 1.02-1.30, P = 0.03).

Sanders KM, Stuart AL, Williamson EJ, et al. JAMA, 2010. PMID 20460620

2010 / Randomized controlled trial

Gestational calcium supplementation lowered maternal bone mineral status during lactation in Gambian women.

In 125 pregnant women with low dietary calcium intakes (roughly 350 mg daily), receiving 1,500 mg calcium daily until delivery resulted in lower postpartum hip bone mineral content (-10.7 +/- 3.7%, P = 0.005), bone area (-3.8 +/- 1.9%, P = 0.05), and bone mineral density (-6.9 +/- 2.6%, P = 0.01) across 12 months of lactation compared to placebo. Supplemented mothers also had greater bone mineral reductions at the spine and radius.

Jarjou LM, Laskey MA, Sawo Y, et al. Am J Clin Nutr, 2010. PMID 20554790

2010 / Controlled clinical trial

A curcumin-phosphatidylcholine complex improved clinical endpoints and inflammatory markers in osteoarthritis patients over eight months.

An eight-month controlled study evaluated the efficacy and safety of Meriva, a curcumin-phosphatidylcholine complex, in 100 osteoarthritis patients. Significant improvements in both clinical endpoints (WOMAC score, Karnofsky Performance Scale Index, and treadmill walking performance) and biochemical endpoints (IL-1beta, IL-6, sCD40L, sVCAM-1, and ESR) were observed for Meriva compared to the control group. The authors reported excellent tolerability.

Belcaro G, Cesarone MR, Dugall M, et al. Altern Med Rev, 2010. PMID 21194249

2009 / Intervention study with 3 groups

Severe weight loss in women increased blood lead levels and bone turnover, while moderate weight loss or weight maintenance did not.

Researchers measured blood lead levels and bone turnover in 73 women before and after 6 months of severe weight loss (S-WL), moderate weight loss (M-WL), or weight maintenance (WM). After severe weight loss (-37.4 +/- 9.3 kg, n=17), blood lead increased by 2.1 +/- 3.9 microg/dl (P < 0.05), reaching levels of 1.3-12.5 microg/dl. M-WL (-5.6 +/- 2.7 kg, n=39) and WM (0.3 +/- 1.3 kg, n=17) did not significantly increase blood lead levels (changes of 0.5 +/- 3.2 and 0.0 +/- 0.7 microg/dl, respectively). Bone turnover markers increased only with severe weight loss and directly correlated with weight loss.

Riedt CS, Buckley BT, Brolin RE, et al. J Expo Sci Environ Epidemiol, 2009. PMID 18322449

2009 / Randomized controlled trial (subgroup analyses)

Glucosamine sulphate was not significantly better than placebo in reducing symptoms or progression in subgroups of hip osteoarthritis patients.

Researchers randomized 222 patients with hip osteoarthritis to receive either 1500 mg of oral glucosamine sulphate or placebo once daily for 2 years. Subgroup analyses examined radiographic severity, localized versus generalized osteoarthritis, pain level, medication use, baseline joint space width, and concomitant knee osteoarthritis. In the predefined subgroups, WOMAC pain, function, and joint space narrowing outcomes were similar between the glucosamine sulphate and placebo groups.

Rozendaal RM, Uitterlinden EJ, van Osch GJ, et al. Osteoarthritis Cartilage, 2009. PMID 18848470

2009 / Randomized, double-blind, placebo-controlled trial

Chondroitins 4 and 6 sulfate significantly reduced joint space width loss and improved pain faster than placebo in patients with knee osteoarthritis over 2 years.

In an international trial, 622 patients with knee osteoarthritis were randomized to receive 800 mg chondroitins 4 and 6 sulfate (CS) or placebo once daily for 2 years. Intent-to-treat analysis showed a significant reduction in minimum joint space width (JSW) loss in the CS group (-0.07 +/- 0.03 mm) compared to placebo (-0.31 +/- 0.04 mm; P < 0.0001). The proportion of patients with radiographic progression >= 0.25 mm was lower with CS (28% vs. 41%, P < 0.0005; relative risk reduction 33%), and pain improved significantly faster in the CS group (P < 0.01) with no differences in safety.

Kahan A, Uebelhart D, De Vathaire F, et al. Arthritis Rheum, 2009. PMID 19180484

2009 / Prospective comparative study with matched groups

Active vitamin D linked to short-term bone marker improvements in Crohn's disease

A prospective study followed 37 inactive Crohn's disease patients in two matched groups receiving either active or plain vitamin D. At six weeks, the active form was linked to lower disease activity index values (69.44 vs 57.0) and C-reactive protein (15.8 vs 7.81 mmol/L, P < 0.05). Markers of bone turnover also decreased and osteoprotegerin rose with the active form. These biochemical changes were stronger at three months but disappeared by month 12.

Miheller P, Muzes G, Hritz I, et al. Inflamm Bowel Dis, 2009. PMID 19408329

2009 / Randomized controlled trial

Curcuma domestica extracts performed similarly to ibuprofen for knee osteoarthritis symptoms.

A randomized trial enrolled 107 patients with primary knee osteoarthritis and assigned them to receive either 2 g of Curcuma domestica extract daily or 800 mg of ibuprofen daily for 6 weeks. Both interventions yielded significant improvements compared to baseline in pain during walking and stair climbing, as well as time spent during a 100-m walk and stair traversal. Adverse event frequencies did not differ significantly between treatments (33.3% vs. 44.2%, p = 0.36).

Kuptniratsaikul V, Thanakhumtorn S, Chinswangwatanakul P, et al. J Altern Complement Med, 2009. PMID 19678780

2009 / Intervention trial

Oral curcumin reduced paraprotein load in half of patients with baseline paraprotein levels over 20 g/L and decreased a bone turnover marker in 27% of patients.

Twenty-six patients with monoclonal gammopathy of undefined significance (MGUS) were administered 4 grams/day of oral curcumin to examine its effects on plasma cells and osteoclasts. Among patients with a paraprotein level >20 g/L, 50% (5 of 10) experienced a 12% to 30% reduction in paraprotein levels during curcumin therapy. Additionally, 27% of patients on curcumin demonstrated a >25% decrease in the bone turnover marker urinary N-telopeptide of type I collagen.

Golombick T, Diamond TH, Badmaev V, et al. Clin Cancer Res, 2009. PMID 19737963

2008 / Randomized controlled trial

Calcium supplementation increased the risk of myocardial infarction in healthy postmenopausal women.

In a five-year randomized controlled trial of 1,471 postmenopausal women, adjudicated myocardial infarction occurred in 21 women receiving calcium versus 10 receiving placebo (relative risk 2.12, 95% CI 1.01 to 4.47). The composite endpoint of myocardial infarction, stroke, or sudden death occurred in 51 calcium recipients versus 35 placebo recipients (relative risk 1.47, 95% CI 0.97 to 2.23). Adding hospital data yielded a composite rate ratio of 1.43 (95% CI 1.01 to 2.04).

Bolland MJ, Barber PA, Doughty RN, et al. BMJ, 2008. PMID 18198394

2008 / Randomized controlled trial

Vitamin D levels and supplementation were not linked to diffuse musculoskeletal pain.

Circulating 25-hydroxyvitamin D was measured in 184 patients with diffuse musculoskeletal pain and 104 osteoarthritis controls, showing no significant difference between groups (29.2 +/- 13.0 vs 28.8 +/- 10.5 ng/mL, P = 0.78). Fifty patients with levels of 20 ng/mL or lower were randomized to ergocalciferol (50,000 IU weekly) or placebo for 3 months. Vitamin D treatment did not significantly improve pain compared to baseline (P = 0.73) or compared to placebo at 3 months (P = 0.12).

Warner AE, Arnspiger SA J Clin Rheumatol, 2008. PMID 18431091

2008 / 24-month double-blind placebo-controlled randomized trial

Glucosamine and/or chondroitin sulfate did not significantly reduce joint space width loss at 2 years in knee osteoarthritis compared to placebo.

In the GAIT trial, 572 patients with knee osteoarthritis were randomized to receive glucosamine (500 mg 3 times daily), chondroitin sulfate (400 mg 3 times daily), their combination, celecoxib (200 mg daily), or placebo over 24 months. Adjusted mean joint space width (JSW) loss at 2 years in the placebo group was 0.166 mm, and no statistically significant difference in mean JSW loss was seen in any treatment group compared with placebo. A trend toward improvement was observed in Kellgren/Lawrence grade 2 knees, but not grade 3 knees. The authors noted study power was diminished by limited sample size, variance of JSW measurement, and smaller than expected JSW loss.

Sawitzke AD, Shi H, Finco MF, et al. Arthritis Rheum, 2008. PMID 18821708

2007 / Randomized placebo-controlled trial

In rheumatoid arthritis patients, 12 weeks of glucosamine improved pain and symptom evaluations but showed no effect on conventional antirheumatic measures.

A randomized placebo-controlled trial evaluated daily administration of 1,500 mg glucosamine hydrochloride versus placebo for 12 weeks alongside conventional medication in 51 rheumatoid arthritis patients. Significant improvements were not observed for joint counts, ACR20 responder rates, ESR, or CRP levels. However, the face scale and visual analogue scale for pain significantly favored the glucosamine group, and serum MMP-3 levels decreased. Patient self-evaluations and physician global evaluations showed noticeable symptom improvements, leading authors to conclude that glucosamine seemed to exert some symptomatic effects without conventional antirheumatic effects.

Nakamura H, Masuko K, Yudoh K, et al. Rheumatol Int, 2007. PMID 16953394

2007 / Randomized controlled trial

A multi-component exercise regimen improved physical functioning and reduced tibial shaft weakening in elderly women.

In a 1-year randomized controlled trial, 149 healthy women aged 70-78 were assigned to resistance training (RES), balance-jumping training (BAL), a combination (COMB), or control (CON). Self-rated physical functioning showed a mean inter-group difference of 10% (95% CI: 0-22%) favoring COMB versus CON. Leg extensor force increased more in RES (14%; 4-25%) and COMB (13%; 3-25%) compared with CON, while dynamic balance improved in BAL (6%; 1-11%) and COMB (8%; 3-12%). There were no inter-group differences in BMC at the proximal femur, but in COMB women training at least twice a week, tibial shaft structure weakened 2% (0-4%) less than in the CON group.

Karinkanta S, Heinonen A, Sievänen H, et al. Osteoporos Int, 2007. PMID 17103296

2007 / Randomized controlled trial

Annual intramuscular vitamin D injection did not prevent non-vertebral fractures in older adults.

A randomized, double-blind, placebo-controlled trial evaluated 9,440 adults aged 75 and older who received an annual intramuscular injection of 300,000 IU vitamin D2 or placebo over 3 years. Vitamin D did not significantly reduce non-vertebral fractures (HR 1.09, 95% CI 0.93-1.28) or falls (HR 0.98, 95% CI 0.93-1.04). However, hip fracture risk was increased in the vitamin D group (HR 1.49, 95% CI 1.02-2.18).

Smith H, Anderson F, Raphael H, et al. Rheumatology (Oxford), 2007. PMID 17998225

2006 / Pharmacokinetic intervention study

Oral glucosamine sulphate yielded peak human serum glucosamine levels of 1.9 to 11.5 micromol/l, far below concentrations often used in in vitro studies.

Eighteen subjects with osteoarthritis were administered 1,500 mg of commercial glucosamine sulphate after an overnight fast, with serum collected over 3 hours (and up to 8 hours in two subjects). Baseline serum glucosamine was below the 0.5 mumol/l detection limit in all subjects. After ingestion, glucosamine was detected in 17 of 18 subjects, rising at 30-45 minutes to a maximum at 90-180 minutes with a range of 1.9-11.5 micromol/l (0.34-2 microg/ml). The authors note this peak concentration is far lower than levels claimed to have in vitro effects.

Biggee BA, Blinn CM, McAlindon TE, et al. Ann Rheum Dis, 2006. PMID 16079170